Episodios

  • Season 4 - Ep6: Extended interview on Whats's new in hypertension?
    Apr 2 2026

    Host: Sabiha Gati

    Guest: Gianfranco Parati

    Want to watch this extended interview? Go to: https://esc365.escardio.org/event/2561?resource=interview

    Want to watch the episode? Go to: https://esc365.escardio.org/event/2561

    Disclaimer:

    ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

    This programme is intended for health care professionals only and is to be used for educational purposes.

    The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

    Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.

    The ESC is not liable for any translated content of this video. The English language always prevails.

    Declarations of interests:

    Stephan Achenbach, Yasmina Bououdina, Sabiha Gati and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

    John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

    Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

    David Duncker has declared to have potential conflicts of interest to report: honorary from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll.

    Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

    Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

    Gianfranco Parati has declared to have potential conflicts of interest to report: Merck Sharp and Dohme, Omron Healthcare, Viatris.

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

    Más Menos
    16 m
  • Season 4 - Ep6: What's new in hypertension? - Why I favour a critical approach in cardiology
    Apr 2 2026

    This episode covers:

    • Cardiology this Week: A concise summary of recent studies
    • What's new in hypertension?
    • Why I favour a critical approach in cardiology
    • Snapshots

    Host: Sabiha Gati

    Guests: Konstantinos Koskinas, Gianfranco Parati, John Mandrola, Yasmina Bououdina

    Want to watch this episode? Go to: https://esc365.escardio.org/event/2561

    Disclaimer:

    ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

    This programme is intended for health care professionals only and is to be used for educational purposes.

    The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

    Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.

    The ESC is not liable for any translated content of this video. The English language always prevails.

    Declarations of interests:

    Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and John Mandrola have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

    John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

    Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

    David Duncker has declared to have potential conflicts of interest to report: honorary from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll.

    Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

    Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

    Gianfranco Parati has declared to have potential conflicts of interest to report: Merck Sharp and Dohme, Omron Healthcare, Viatris.

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

    Más Menos
    22 m
  • Season 4 - Ep5: SPECIAL Atrial Fibrillation: AF burden: clinical relevance - Pulsed Field Ablation - Treatment following Afib ablation
    Mar 19 2026

    This Special Episode on Atrial Fibrillation covers:

    • Cardiology this Week: A concise summary of recent studies
    • Atrial fibrillation burden: clinical relevance of a new outcome
    • Pulsed field ablation: game changer?
    • Drug treatment following atrial fibrillation ablation
    • Spotlight: Holiday Heart Syndrome

    Host: Rick Grobbee

    Guests: Rick Grobbee, Konstantinos Koskinas, Jason Andrade, Arian Sultan, Michiel Rienstra

    Want to watch that special episode? Go to: https://esc365.escardio.org/event/2549

    Disclaimer:

    ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

    This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

    Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.

    The ESC is not liable for any translated content of this video. The English language always prevails.

    Declarations of interests: Stephan Achenbach, Jason Andrade, Yasmina Bououdina, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

    John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

    Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

    Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

    Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Michiel Rienstra has declared to have potential conflicts of interest to report: consultancy fees from Bayer (OCEANIC-AF national PI) , InCarda Therapeutics (RESTORE-SR national PI), Novartis to the institution. Speaker fee from Daiichi-Sankyo, Pfizer to the institution. Unrestricted research grant from the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0118 EmbRACE. Unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001. Unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED-CVD (CVON2017-11). Unrestricted research grant from Top Sector Life Sciences & Health to the Dutch Heart Foundation (PPP Allowance; CVON-AI (2018B017). Unrestricted research grant from the European Union's Horizon 2020 research and innovation programme under grant agreement; EHRA-PATHS (945260). This research is funded by the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01 -002 -2022 -0118 EmbRACE.

    Emma Svennberg has declared to have potential conflicts

    Más Menos
    28 m
  • Season 4 - Ep4: Extended interview on The future of guidelines in an era of big data and AI
    Mar 5 2026

    Host: Sabiha Gati

    Guest: Thomas F. Luescher

    Want to watch that extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview

    Want to watch the full episode? Go to: https://esc365.escardio.org/event/2556

    Disclaimer:

    ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

    This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

    Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

    All declarations of interest are listed at the end of the episode.

    The ESC is not liable for any translated content of this video. The English language always prevails.

    Declarations of interests:

    Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

    Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

    Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

    Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

    Más Menos
    10 m
  • Season 4 - Ep4: The future of guidelines in an era of big data and AI - Exercise in hypertrophic cardiomyopathy
    Mar 5 2026

    This episode covers:

    • Cardiology this Week: A concise summary of recent studies
    • The future of guidelines in an era of big data and AI
    • Exercise in hypertrophic cardiomyopathy
    • Snapshots

    Host: Sabiha Gati

    Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach

    Want to watch that episode? Go to: https://esc365.escardio.org/event/2556

    Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview

    Disclaimer:

    ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

    This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

    Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

    All declarations of interest are listed at the end of the episode.

    The ESC is not liable for any translated content of this video. The English language always prevails.

    Declarations of interests:

    Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

    Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

    Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

    Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

    Más Menos
    19 m
  • Season 4 - Ep3: Extended interview on Atrial septal defects in adults
    Feb 19 2026

    Host: Rick Grobbee

    Guest: Annemien van den Bosch

    Want to watch that extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview

    Want to watch the full episode? Go to: https://esc365.escardio.org/event/2552

    Disclaimer:

    ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

    This programme is intended for health care professionals only and is to be used for educational purposes.

    The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.

    The ESC is not liable for any translated content of this video. The English language always prevails.

    Declarations of interests:

    Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

    John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

    Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

    Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

    Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

    Más Menos
    17 m
  • Season 4 - Ep3: Atrial septal defects in adults - Conservative and invasive management of chronic coronary syndromes
    Feb 19 2026

    This episode covers:

    Cardiology This Week: A concise summary of recent studies

    Atrial septal defects in adults

    Conservative and invasive management of chronic coronary syndromes

    Milestones: 4S trial

    Host: Rick Grobbee

    Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran

    Want to watch the episode? Go to: https://esc365.escardio.org/event/2552

    Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview

    Disclaimer:

    ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

    This programme is intended for health care professionals only and is to be used for educational purposes.

    The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.

    The ESC is not liable for any translated content of this video. The English language always prevails.

    Declarations of interests:

    Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

    Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals.

    John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

    Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

    Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

    Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

    Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity <1% in: Stel, ControlRad (spouse) ; No Fees from: SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director) ; Honorarium:AMA - JAMA Cardiology (Associate Editor), ACC (Vice President, BOT Member, SC Member CTR Program).

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

    Más Menos
    28 m
  • Season 4 - Ep2: Extended interview on Lp(a) and aortic valve stenosis
    Feb 5 2026

    Host: Emer Joyce

    Guest: Borge Nordestgaard

    Want to watch that extended interview on Lp(a) and aortic valve stenosis, go to: https://esc365.escardio.org/event/2548?resource=interview

    Want to watch the full episode? Go to: https://esc365.escardio.org/event/2548

    Disclaimer:

    ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner.

    This programme is intended for health care professionals only and is to be used for educational purposes.

    The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

    All declarations of interest are listed at the end of the episode.

    The ESC is not liable for any translated content of this video. The English language always prevails.

    Declarations of interests:

    Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

    Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

    John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.

    Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo.

    Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1.

    Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.

    Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck.

    Borge Nordestgaard has declared to have potential conflicts of interest to report: consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, Marea, Merck, Torrent, USV – honoraria used for research.

    Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

    Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

    Más Menos
    9 m